HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

HUTCHMED (China) LimitedNASDAQ: HCM

Net Change in Cash · Q2 FY2025 · quarter ended Jun 2025

Net change in cash outflow shrinks to $0

Q2 FY2025 net change in cash was $0, compared with $203.95M a year earlier. Trailing-twelve-month net change in cash was -$203.95M. Over 3 fiscal years it compounded at +8.7% a year.

Context

  • Net change in cash amounted to 15.0% of revenue in FY2025, down 5.5 pp from a year earlier.
  • Net change in cash grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$50.99M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2025
$0— QoQ
Last fiscal yearDec 2025
-$82.63M-36.3% YoY
LTMJun 2025
-$203.95M-736.8% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-36.3%——
3-year CAGR+8.7%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(82.63M) USD
Year-over-year change
+36.3%

Net Change in Cash vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -736.8% is the lowest of 9, against a peer median of +68.2%.
  • Net change in cash amounts to 33.9% of revenue for HCM, versus a peer median of 28.5%.
HCM Competitors
Net Change in Cash for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$2.03B USD+109.5%+16.4%34.8%
BNTXBioNTech SELTM Jun 2026€774.56M EUR-183.0%—29.3%
AAPGAscentage Pharma Group InternationalFY2025CN¥302.68M CNY+308.8%—54.2%
GMABGenmab A/SLTM Jun 2026$207.09M USD—-28.3%5.0%
HCMHUTCHMED (China) LimitedLTM Jun 2025$203.95M USD-736.8%+8.7%33.9%
LEGNLegend Biotech CorporationLTM Sep 2026$181.76M USD+200.8%+85.0%13.4%
ZLABZai Lab LimitedLTM Jun 2026$124.74M USD-222.0%+73.0%27.7%
EXELExelixis, Inc.LTM Jul 2026$117.02M USD+443.9%—4.8%
RCUSArcus Biosciences, Inc.LTM Jun 2026$98M USD-206.5%+7.5%83.8%
ANLAdlai Nortye Ltd.LTM Jun 2024$37.95M USD—+20.2%584.8%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$27.53M USD+26.9%—12.2%
Peer median (excluding HCM) —+68.2%+18.3%28.5%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.04M)(360.39M)100.78M37.73M458.12M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
Deferred Income Tax(115.14M)0(102.76M)00
Stock-Based Compensation41.99M30.59M36.6M21.61M15.29M
Change in Working Capital32.46M58.7M71.15M(62.17M)(61.02M)
Accounts Receivables(35.63M)(14.45M)(21.34M)(41.57M)28.94M
Inventory(16M)(21.21M)4.14M(772K)9.57M
Accounts Payables9.57M29.94M(32.54M)03.02M
Other Working Capital74.53M64.04M120.89M(19.82M)(102.55M)
Other Non-Cash Items(3.68M)(6.17M)105.28M(9.01M)(490.56M)
Operating Cash Flow(204.22M)(268.6M)219.26M497K(64.83M)
Capital Expenditures(16.76M)(36.66M)(32.61M)(17.93M)(14.19M)
Acquisitions (Net)159.12M324K(2.99M)028.07K
Purchases of Investments(1.37B)(1.2B)(1.63B)(1.85B)(2.75B)
Sales of Investments921.36M1.52B1.37B1.77B2.74B
Other Investing Activities930K16.49M29.5M1.28M0
Investing Cash Flow(306.32M)296.59M(291.14M)(96.06M)(29.49M)
Debt Repayment(579.77K)(9.17M)61.71M5.61M6.27M
Common Stock Issued717.32M174K5.09M790K1.58M
Common Stock Repurchased(27.31M)(48.08M)(9.07M)(36.06M)0
Dividends Paid(99.74M)(87.44M)000
Other Financing Activities60.34M61.75M(9.07M)(1M)0
Financing Cash Flow650.03M(82.76M)48.66M(30.67M)7.86M
Effect of Forex Changes2.43M(9.49M)(6.47M)(3.4M)3.83M
Net Change in Cash141.91M(64.26M)(29.69M)(129.63M)(82.63M)
Free Cash Flow(220.98M)(305.26M)186.65M(17.44M)(79.01M)

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.